Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Attention-deficit hyperactivity disorder is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.

The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market is estimated to account for US$ 19,293.6 Mn in terms of value and is expected to reach US$ 29,996.9 Mn by the end of 2027.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Drivers

Increasing prevalence of attention-deficit/hyperactivity disorder is expected to propel growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market over the forecast period. For instance, according to the study, ‘Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder among Adults and Children of Different Racial and Ethnic Groups.’ Published in the JAMA Network Open in November 2019, prevalence of attention-deficit/hyperactivity disorder in adults among 7 racial/ethnic groups increased from 0.43% in 2007 to 0.96% in 2016.

Moreover, R&D in attention-deficit/hyperactivity disorder is also expected to aid in growth of the market. For instance, in April 2020, American BriVision (Holding) Corporation announced that a site monitoring visit was conducted on March 10 and March 11, 2020 at the University of California San Francisco (UCSF) Medical Center for ABV-1505 Phase II Part I clinical trial, under the U.S. Food and Drug Administration (FDA) clinical protocol code BLI-1008-001, for Adult Attention-Deficit Hyperactivity Disorder (ADHD).

Stimulants held dominant position in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market in 2019, accounting for 86.1% share in terms of value, followed by non-stimulants, respectively.

Figure 1. Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Share (%), by Value, by Drug Type, 2019

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics  | Coherent Market Insights

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Restraints

Drug abuse (stimulants) is expected to hinder growth of the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. Stimulants function by increasing dopamine levels in the brain, a neurotransmitter associated with pleasure, attention and movement. If stimulants are taken in doses and via routes other than prescribed, rapid and highly amplified increase in dopamine levels is achieved causing disruption in normal communication between brain cells resulting in euphoria, decreased appetite and wakefulness, which increases the risk of addiction.

Moreover, less availability of non-stimulant drugs is also expected to limit the demand for attention-deficit/hyperactivity disorder therapeutics. Although there is a risk of drug abuse associated with stimulants attention-deficit/hyperactivity disorder drugs, it currently accounts for a higher market share as compared to non-stimulants attention-deficit/hyperactivity disorder drugs. This is due to low availability of non-stimulants attention-deficit/hyperactivity disorder drugs in various geographies.

request-sample

Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 18,133.1 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.5% 2027 Value Projection: US$ 29,996.9 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Drug Type:
    • Stimulants: Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate.
    • Non-stimulants: Atomoxetine, Bupropion, Guanfacine, Clonidine.
  • By Age Group: Pediatric and Adolescent, Adults.
  • By Distribution Channel: Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, e-Commerce.
Companies covered:

Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.

Growth Drivers:
  • Increasing prevalence of attention-deficit/hyperactivity disorder
  • Increasing research and development
Restraints & Challenges:
  • Side effects
  • Drug abuse risks

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Opportunities 

Integration of attention-deficit/hyperactivity disorder knowledge improvement program into teachers’ educational programs is expected to offer lucrative growth opportunities for players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market. For instance, in August 2020, researchers from Joint Program of Saudi Board in Community Medicine, Saudi Arabia, reported that only 16% and 22% of trial and control groups, respectively, showed adequate baseline knowledge about attention-deficit/hyperactivity disorder and that knowledge of teachers in the trial group significantly improved immediately after the intervention.

Moreover, adoption of antioxidants in attention-deficit/hyperactivity disorder treatment is also expected to aid in growth of the market. For instance, in February 2020, researchers from CONACYT-Hospital Infantil de México Federico Gómez, Mexico, reported that antioxidants could be considered as a multi-target adjuvant therapy for attention-deficit/hyperactivity disorder.  

The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market was valued at US$ 18,133.1 Mn in 2019 and is forecast to reach a value of US$ 29,996.9 Mn by 2027 at a CAGR of 6.5% between 2020 and 2027.

Figure 2. Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market are focused on R&D of new therapies to expand their product portfolio. For instance, in July 2020, American BriVision (Holding) Corporation reported the completion of the ABV-1505 Phase II Part I clinical trial for the treatment of adult attention-deficit/hyperactivity disorder.

Major players in the market are also focused on providing support programs during the COVID-19 pandemic. For instance, in April 2020, Otsuka Pharmaceutical Co., Ltd. extended its patient support programs, Otsuka Patient Support and Otsuka Patient Assistance Foundation, to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 pandemic.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Competitive Landscape

Major players operating in the global attention-deficit/hyperactivity disorder (ADHD) therapeutics market include, Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.

Global Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market: Key Developments

Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in March 2020, RespireRx Pharmaceuticals Inc. partnered with the UWM Research Foundation, Inc. to license GABA(A) receptor allosteric neuromodulator intellectual property from the UWM Research Foundation, Inc.

Attention deficit hyperactivity disorder (ADHD) is a neural disorder. The disorder is characterized by impulsiveness, hyperactivity, and attention difficulty. Treatment of ADHD involves a combination of counseling, medications, and lifestyle changes. ADHD is the most commonly diagnosed mental disorder in adults and children with the exact cause being unidentified in the majority of cases. Researchers at the National Institute of Mental Health (NIMH) suggest the factors affecting mental illness include heredity, brain injuries, low birth weight, drugs use during pregnancy and exposure to environmental toxins such, as lead at young age. The currently available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments helps in reducing symptoms with improved functioning of patient.

Restraints of the Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Major factors hampering the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period constitutes of side effects, and drug abuse risks.

Key features of the study:

  • This report provides in-depth analysis of the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type:
    • Stimulants
      • Amphetamine
      • Methylphenidate
      • Dextroamphetamine
      • Dexmethylphenidate
      • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Atomoxetine
      • Bupropion
      • Guanfacine
      • Clonidine
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Age Group:
    • Pediatric and Adolescent
    • Adults
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Distribution Channel:
    • Specialty Clinics
    • Hospital Pharmacies
    • Retail Pharmacies
    • e-Commerce
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Geography:
    • North America
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Stimulants
          • Amphetamine
          • Methylphenidate
          • Dextroamphetamine
          • Dexmethylphenidate
          • Lisdexamfetamine Dimesylate
        • Non-stimulants
          • Atomoxetine
          • Bupropion
          • Guanfacine
          • Clonidine
      • By Age Group
        • Pediatric and Adolescent
        • Adults
      • By Distribution Channel
        • Specialty Clinics
        • Hospital Pharmacies
        • Retail Pharmacies
        • e-Commerce
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Amedra Pharmaceuticals LLC*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Eli Lilly and Company
    • Janssen Pharmaceuticals, Inc.
    • Noven Pharmaceuticals, Inc.
    • RespireRx Pharmaceuticals Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • American BriVision (Holding) Corporation
    • Novartis Pharmaceuticals Corporation
    • Shire Plc
    • GlaxoSmithKline
    • Celltech Group Ltd.
    • Purdue Pharma L.P.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Age Group
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Stimulants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Amphetamine
        • Methylphenidate
        • Dextroamphetamine
        • Dexmethylphenidate
        • Lisdexamfetamine Dimesylate
    • Non-stimulants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Atomoxetine
        • Bupropion
        • Guanfacine
        • Clonidine
  5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Age Group, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Pediatric and Adolescent
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Adults
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • e-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Amedra Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Janssen Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Noven Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • RespireRx Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Otsuka Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • American BriVision (Holding) Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis Pharmaceuticals Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Shire Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Celltech Group Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Purdue Pharma L.P.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 34 market data tables and 24 figures on “Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Global forecast to 2027.

Frequently Asked Questions

The global attention-deficit/hyperactivity disorder (ADHD) therapeutics market was valued at US$ 18,133.1 Mn in 2019 and is forecast to reach a value of US$ 29,996.9 Mn by 2027 at a CAGR of 6.5% between 2020 and 2027.
Major factor driving the growth of global attention-deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period include increasing prevalence of attention-deficit/hyperactivity disorder, and increasing research and development.
Major factors hampering the growth of the attention-deficit hyperactivity disorder (ADHD) Therapeutics market during the forecast period constitutes of side effects, and drug abuse risks.
Stimulants held dominant position in the global attention-deficit hyperactivity disorder (ADHD) Therapeutics market in 2019.
North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner